Overview

Data as of April 03, 2020 04:46 am EDT

Press Releases

Summary Toggle Madrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights

February 26, 2020

CONSHOHOCKEN, Pa. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2019 financial results and highlights: “Madrigal made significant progress during 2019 in executing our business strategy and advancing the development
Summary Toggle Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH (

December 18, 2019

-- MAESTRO-NAFLD-1 is the second resmetirom Phase 3 clinical trial in patients with NASH and presumed NASH and follows MAESTRO-NASH, a Phase 3 multi-center, double-blind, randomized, placebo-controlled study in patients with non-alcoholic steatohepatitis ( NASH ) and fibrosis, that was initiated in
Summary Toggle Madrigal Pharmaceuticals Announces Pricing of Secondary Offering

December 10, 2019

WEST CONSHOHOCKEN, Pa. , Dec. 10, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of

Filing date	Form	Description	Filing Group	View
July 05, 2017	D		Other	0001288452-17-000002.rtf 0001288452-17-000002.pdf
December 12, 2019	424B7	424B7	Registration Statements	0001193125-19-312878.rtf 0001193125-19-312878.xls 0001193125-19-312878.pdf
April 17, 2013	PRE 14A	A preliminary proxy statement providing notification matters to be brought to a vote	Proxy Filings	0001047469-13-004491.rtf 0001047469-13-004491.xls 0001047469-13-004491.pdf